October 20 at 8:30 am PDT / 11:30 am EDT 

Biomedical research relies on commercial investment, grant funding, and private donations to accelerate drug development, run clinical trials, and support innovation in health technologies. Coordinated approaches are needed to ensure rapid transfer of treatments to patients. The pandemic has revealed inequitable practices in medical care and research. Health equity must be embedded in medical R&D. What incentives induce funders to support equity in research? How can finance and business align with philanthropy in health equity investment? What metrics would predict the impact of finance, business, grant funding, and sponsorship on equity in biomedical R&D? Panelists involved in industry, research, and policy share perspectives on the impact of investing in health equity. They will appraise current and future funding aimed at improving outcomes among patients who experience the widest health and socioeconomic disparities.

Moderator

Yasmeen Long
Director, FasterCures, Milken Institute

Speakers

Mark Blumling
CEO, President and Founder, Headlands Research

LaTese Briggs
Vice President and Chief Philanthropy Officer, Executive Leadership Council

Amanda Castel
Professor, Department of Epidemiology, George Washington University

Wayne A.I. Frederick
President, Howard University